B-RAF with PLX4032
From Proteopedia
(Difference between revisions)
| Line 5: | Line 5: | ||
<scene name='B-RAF_with_PLX4032/Plx_4032_only/1'>PLX 4032</scene><br> | <scene name='B-RAF_with_PLX4032/Plx_4032_only/1'>PLX 4032</scene><br> | ||
| + | <scene name='B-RAF_with_PLX4032/Mutated_v600e/1'>TextToBeDisplayed</scene> <br> | ||
<scene name='B-RAF_with_PLX4032/V600e_mutation/1'>V600E mutation</scene><br> | <scene name='B-RAF_with_PLX4032/V600e_mutation/1'>V600E mutation</scene><br> | ||
<scene name='B-RAF_with_PLX4032/Plx4032_n/1'>PLX4032 Sulfonamide N</scene> <br> | <scene name='B-RAF_with_PLX4032/Plx4032_n/1'>PLX4032 Sulfonamide N</scene> <br> | ||
Revision as of 01:42, 29 September 2010
B-RAF with PLX4032
PLX4032 is a newly synthesized drug that is being used to treat malignant melanonma with a specific mutation. The mutation is B-RAF^(V600E). This drug is highly selective for this mutation and will not bind to wild type B-RAF.
|
|
